Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma

NCT05148572 | Active Not Recruiting DMC

• 1 other identifier: AHCC11 PROSECT
• Study Type: observational
• Target: 101
• Locations: 1 country
• Sites: 6

Brief Summary

Hepatocellular carcinoma (HCC) is the 4th most common cause of cancer death globally but only 20% are diagnosed in its early stages where curative treatment can be carried out. Current standard-of-care surveillance of patients at high risk of developing HCC with 6-monthly serum alpha-fetoprotein (AFP) and ultrasound imaging (US) has a sensitivity of approximately 63% for detecting early HCC. There is an urgent need for a more efficacious and convenient modality of surveillance of high-risk patients to diagnose HCC at an early stage. In another study (AHCC10 ELEGANCE, NCT04965259), 2,000 patients at risk of developing HCC will be enrolled to develop the 1st miRNA in-vitro diagnostic (IVD) kit for HCC that has higher accuracy and better ease of use compared with the extant combination of AFP and US. This prospective study will act as a positive control to the AHCC10 ELEGANCE Study and aims to address the absence of efficacious modalities of surveillance by validating a panel of circulating miRNA biomarkers signatures with histologically proven HCC. This study will determine progressive changes in the profiles of miRNA signatures pre- and post- surgical resection to identify signatures predictive of recurrence. Additionally, this study also aims to identify changes in key metabolites and microbiome with correlation to changes in choline, bile acid and tryptophan metabolic pathways with changes in the composition and function of gut microbiota to establish actionable biomarkers that can predict HCC recurrence.

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma (HCC); Recurrence; miRNA biomarkers; Gut microbiota; Metabolites; Microbiome biomarkers; Circulating biomarkers

Outcome Measures

Primary Outcomes (3)

• miRNA biomarker signatures diagnostic for HCC or for recurrence prediction.

  Changes in the profile of circulating micro-RNA biomarkers pre- and post- surgical resection.

  Baseline and every 6 monthly thereafter, up to 12 months.

• Gut microbiome profiling for recurrence prediction.

  Differences in the profile of gut microbiota among HCC and healthy population retrieved from database.

  Baseline and every 6 monthly thereafter, up to 12 months.

• Metabolome profiling for recurrence prediction.

  Changes in the profile of metabolome in urine and plasma pre- and post- surgical resection.

  Baseline and every 6 monthly thereafter, up to 12 months.

Eligibility Criteria

• Age: 21 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with diagnosis of hepatocellular carcinoma (HCC) confirmed by histology at surgical resection.

You may qualify if:

• The patient is male or female patients, 21 to 90 years of age at the time of signature of the informed consent form.
• The patient has clinically AND histologically proven HCC.
• The patient has R0 or R1 resection on histology.
• The patient has Child-Pugh \<= 7 points without clinical ascites before surgery.
• The patient has ECOG performance status 0-1 before surgery.
• The patient is scheduled for liver resection within 6 weeks of signing screening informed consent form.
• The patient has received no anti-cancer specific treatment for HCC before the surgery (eg. previous liver resection, loco-regional therapy such as RFA, TACE, SIRT, radiotherapy, immunotherapy, chemotherapy or neo-adjuvant chemotherapy), other than the planned surgery. However, patient who has received previous HCC treatment more than 5 years ago is deemed to have a de-novo liver tumour and therefore can be included.
• The patient is able to comply with scheduled visits, assessments and other study procedures.
• The patient is willing to provide informed consent before enrolment in the study.

You may not qualify if:

• The patient has previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and highly likely to have been cured.
• The patient has active hepatic encephalopathy at time of enrolment.
• The patient has received a major organ allograft.
• The patient is known to be positive for the Human Immunodeficiency Virus (HIV).
• The patient has an uncontrolled bleeding disorder.
• The patient has uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease or myocardial infarction) or uncontrolled arrhythmia at the time of enrolment.
• The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the study procedures.
• The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
• The patient has received any investigational or non-registered medicinal product (drug or vaccine) within the 30 days preceding the date of enrolment.
• For female patients: the patient is pregnant or lactating.
• The patient is unable to provide informed consent or refuse blood taking.
• The patient has any other condition which, in the opinion of the Investigators, would make the patient unsuitable for enrolment or could interfere with completion of the study.

Sponsors & Collaborators

• National Cancer Centre, Singapore: lead
• Duke-NUS Graduate Medical School: collaborator
• Singapore Phenome Centre: collaborator
• Nanyang Technological University: collaborator
• MiRXES Pte Ltd: collaborator
• Asian Microbiome Library (AMiLi) Pte Ltd: collaborator

Study Sites (6)

National University Hospital

Singapore, 119228, Singapore

Location

National Cancer Centre Singapore

Singapore, 168583, Singapore

Location

Singapore General Hospital

Singapore, 169608, Singapore

Location

Tan Tock Seng Hospital

Singapore, 308433, Singapore

Location

Changi General Hospital

Singapore, 529889, Singapore

Location

Sengkang General Hospital

Singapore, 544886, Singapore

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples shall be used for relevant laboratory assessments. Blood, urine and stool samples shall be used for miRNA, microbiome and metabolome profiling.

MeSH Terms

Conditions

Carcinoma, Hepatocellular; Recurrence

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Pierce CHOW, MD, PhD

  National Cancer Centre, Singapore

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 16, 2021
• First Posted: December 8, 2021
• Study Start: November 10, 2021
• Primary Completion: April 30, 2025
• Study Completion (Estimated): December 21, 2026
• Last Updated: July 2, 2025

Record last verified: 2025-06

Locations

SG (6)